Market Place
Sourcing Support
CytoDyn Shares Leronlimab Data for Metastatic TNBC Cancer
20 Apr 2026 //
GLOBENEWSWIRE
Cytodyn To Present At The AACR Annual Meeting 2026
14 Apr 2026 //
GLOBENEWSWIRE
CytoDyn Presents at AACR Special Conference in Cancer Research
24 Mar 2026 //
GLOBENEWSWIRE
CytoDyn Launches Funding For Triple-Negative Breast Cancer
27 Jan 2026 //
GLOBENEWSWIRE
Ex-Cytodyn CEO Sentenced As Alleged Co-Conspirator Wins New Trial
26 Jan 2026 //
PRESS RELEASE
CytoDyn Showcases PD-L1 Upregulation, Survival in mTNBC at SABCS
08 Dec 2025 //
GLOBENEWSWIRE
CytoDyn Presents Leronlimab Data in Metastatic TNBC at SABCS
24 Nov 2025 //
GLOBENEWSWIRE
CytoDyn To Present At LD Micro Investor Conference
09 Oct 2025 //
GLOBENEWSWIRE
September 2025 Letter To Shareholders
30 Sep 2025 //
GLOBENEWSWIRE
CytoDyn to Present Leronlimab Effects in TNBC at AACR Conference
25 Sep 2025 //
GLOBENEWSWIRE
CytoDyn to Present at AACR Cancer Immunity Mechanisms Conference
16 Sep 2025 //
GLOBENEWSWIRE
CytoDyn to Present at the H.C. Wainwright Investment Conference
28 Aug 2025 //
GLOBENEWSWIRE
CytoDyn Reports Positive Survival Data in Colorectal Cancer
01 Jul 2025 //
GLOBENEWSWIRE
CytoDyn Starts Phase II Trial in Colorectal Cancer
24 Jun 2025 //
GLOBENEWSWIRE
CytoDyn Releases ESMO Breast Cancer Meeting Poster
15 May 2025 //
GLOBENEWSWIRE
CytoDyn Reveals New Mechanism of Leronlimab for Solid Tumors
13 May 2025 //
GLOBENEWSWIRE
CytoDyn names Robert E. Hoffman as CFO
06 May 2025 //
GLOBENEWSWIRE
CytoDyn`s Survival Observations In mTNBC Patients On Leronlimab
24 Feb 2025 //
GLOBENEWSWIRE
CytoDyn Announces Statistically Significant Fibrosis Reversal
06 Feb 2025 //
GLOBENEWSWIRE
Jury convicts 2 former biopharma leaders of fraud
10 Dec 2024 //
FIERCE BIOTECH
CytoDyn Appoints Richard Pestell as Oncology Lead Consultant
25 Nov 2024 //
GLOBENEWSWIRE
CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
04 Nov 2024 //
GLOBENEWSWIRE
CytoDyn Appoints Dr. Melissa Palmer as Hepatology Consultant
30 Oct 2024 //
GLOBENEWSWIRE
CytoDyn Appoints Dr. Lataillade As Head Of Clinical Development
08 Oct 2024 //
GLOBENEWSWIRE
CytoDyn Announces Abstract On Leronlimab`s Potential
07 Oct 2024 //
GLOBENEWSWIRE
CytoDyn Engages Syneos Health For Phase II Oncology Trial
04 Oct 2024 //
GLOBENEWSWIRE
CytoDyn Announces Preliminary Findings in Study with SMC Lab
24 Sep 2024 //
GLOBENEWSWIRE
September 2024 Letter to Shareholders
09 Sep 2024 //
GLOBENEWSWIRE
CytoDyn Engages Leading CRO For Phase II Inflammation Trial
23 Aug 2024 //
GLOBENEWSWIRE
CytoDyn Completes FDA Meeting On Leronlimab Colorectal Cancer Study
12 Aug 2024 //
GLOBENEWSWIRE
CytoDyn Announces Initiation of Pre-Clinical Study in Glioblastoma
01 Feb 2024 //
GLOBENEWSWIRE
